Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 687)
Posted On: 09/04/2020 1:43:47 AM
Post# of 154938
Posted By: KenChowder
Request some help to inform NIH researcher

Hello Board. I have been in contact with an Alzheimer researcher with the NIH. Interestingly if terrifically annoyingly, she's never thought about Leronlimab. She writes:
"I am not sure how helpful it would be..the compound blocks CC5 [sic], a receptor on the surface of immune cells which can serve as a viral entry site (HIV and COVID-19). I do not immediately see a good application for AD. I have not thought about it at all. I believe there is some cognitive improvement in COVID-infected patients, but that is likely because it has blocked viral entry and reduced infection and its neurological effects."

I know the key is neuroinflammation, which is important in AD, and RANTES is a cytokine and CCR5 a cytokine receptor, and some cytokines help regulate immune cell migration to inflammation sites. But I'm far from a doc, and don't have a good and short knowledgeable quote I can send her that demonstrates that Leron would be good to investigate. She is of course superbusy. Can anyone show me to or offer such a short response? Many thanks in advance.

Just trying to spread the word....













(4)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site